TendoNova
Atlanta, US · Founded 2017 · 4 known investors
Find your way into TendoNova
Sign up to see every warm intro you have to TendoNova
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TendoNova team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TendoNova develops microinvasive medical technology, including its Ocelot Nano device, to treat chronic tendon pain in patients. The company targets clinical use for patients with tendon injuries, including athletes.
Founders & leadership

Board
Investors · 4
How we know: Arieal Southeast Angel Partners's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 7 rounds · 2019–2024
▶$270KraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
- Jeff ClarkDirector
- Jonathan ShawDirector
- Ian CampbellExecutive Officer, Director
- Peter HaalandDirector
- Offering amount
- $400K
- Amount sold
- $270K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$762KraisedMay 2024 · 6 investors · BiotechnologyRule 506(b)
- Jonathan ShawDirector
- Jeff ClarkDirector
- Mark SamuelsExecutive Officer, Director
- Ian CampbellDirector
- Peter HaalandDirector
- Offering amount
- $1.1M
- Amount sold
- $762K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedJan 2024 · 10 investors · BiotechnologyRule 506(b)
- Shawna KhouriDirector
- Mark SamuelsExecutive Officer, Director
- Jonathan ShawDirector
- Luka GrujicDirector
- Peter HaalandDirector
- Brett RogersDirector
- Louis MaliceDirector
- Offering amount
- $500K
- Amount sold
- $250K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedOct 2023 · 3 investors · BiotechnologyRule 506(b)
- Luka GrujicDirector
- Jonathan ShawDirector
- Peter HaalandDirector
- Louis MaliceDirector
- Shawna KhouriDirector
- Brett RogersDirector
- Mark SamuelsExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $300K
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$440KraisedDec 2022 · 8 investors · BiotechnologyRule 506(b)
- Luka GrujicDirector
- Shawna KhouriDirector
- Jonathan ShawDirector
- Louis MaliceDirector
- Peter HaalandDirector
- Brett RogersDirector
- Mark SamuelsExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $440K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$446.3KraisedAug 2022 · 11 investors · BiotechnologyRule 506(b)
- Jonathan ShawDirector
- Shawna KhouriDirector
- Luka GrujicDirector
- Brett RogersDirector
- Louis MaliceDirector
- Mark SamuelsExecutive Officer, Director
- Peter HaalandDirector
- Offering amount
- $2M
- Amount sold
- $446.3K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.4MraisedFeb 2021 · 13 investors · BiotechnologyRule 506(b)
- Mark SamuelsExecutive Officer
- Peter HaalandDirector
- Jonathan ShawExecutive Officer, Director
- Louis MaliceDirector
- Luka GrujicDirector
- Shawna KhouriDirector
- Brett RogersDirector
- Offering amount
- $1.5M
- Amount sold
- $1.4M
- Minimum investment
- $10K
- Proceeds to insiders
- $50K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as TendoNova.
In the news
Frequently asked questions
- What does TendoNova do?
- TendoNova develops microinvasive medical technology, including its Ocelot Nano device, to treat chronic tendon pain in patients. The company targets clinical use for patients with tendon injuries, including athletes.
- Who are TendoNova's investors?
- TendoNova's investors include Arieal Southeast Angel Partners, Walnut Venture Associates, InnerProduct Partners, VentureSouth.
- How much funding has TendoNova raised?
- TendoNova has disclosed $3.8M raised across 7 rounds.
- Where is TendoNova headquartered?
- TendoNova is headquartered in Atlanta, US.





